mielozitidina 100 mg polvo para solucion inyectable
biotoscana farma de peru s.a.c. - azacitidina; - polvo para solucion inyectable - por vial - azacitidina
azacord 100mg polvo para suspension inyectable
accord healthcare s.a.c. - droguerÍa - azacitidina; - polvo para suspension inyectable - por vial mg - - azacitidina
vidaza 100 mg polvo para suspension inyectable
bristol-myers squibb peru s.a. - droguerÍa - polvo para suspension inyectable - por vial - - azacitidina
azacitidina 100mg/vial polvo para suspension inyectable
advance scientific del peru s.a.c. - droguerÍa - polvo para suspension inyectable - por vial - - azacitidina
sindazatina 100 mg polvo para concentrado para solucion para perfusion
global med farma s.a.c. - droguerÍa - polvo para concentrado para solucion para perfusion - por vial - - azacitidina
onureg
bristol-myers squibb pharma eeig - azacitidina - leucemia, mieloide, aguda - agentes antineoplásicos - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).
azacitidina 100mg polvo para solucion inyectable
perulab s.a. - droguerÍa - azacitidina; - polvo para solucion inyectable - por vial 1.00 - - azacitidina
iclacitidina 100 mg polvo para solucion inyectable
mega labs latam s.a. - azacitidina; - polvo para solucion inyectable - por vial - azacitidina
vidaza
bristol-myers squibb pharma eeig - azacitidina - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agentes antineoplásicos - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.
azacitidine celgene
celgene europe bv - azacitidina - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agentes antineoplásicos - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.